Bayer AG
Operates as a diversified life sciences company developing and selling pharmaceuticals for cardiology, oncology, and women's health; over-the-counter consumer health products; and crop protection solutions.
As of Sep 1, 2026
Summary
Bayer AG is a diversified German healthcare company with operations spanning pharmaceuticals, crop science, and consumer health products. The stock is trading at a neutral technical position following a one-month gain of 2.1 per cent, though it has delivered a notably strong one-year return of 76.5 per cent. At a market capitalisation of €48.2 billion, Bayer remains one of Europe's largest healthcare businesses.
Price history
As of Aug 31, 2026
Performance
-0.33%
+1.16%
+2.06%
+41.33%
+32.88%
+76.53%
As of Aug 31, 2026
Technical indicators
- 55.8
- -0.07Bearish
- 50: 48.23 · 200: 40.88Bullish
- €47.44 / €49.45
Technical Bias
Bayer AG's technical picture is split three ways: momentum sits neutral around 55.8 on the RSI, the MACD shows mild bearish pressure at -0.07, whilst the moving average structure (50-day above 200-day) tilts bullish. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 31, 2026
Fundamentals
- €48.2B
- —
- €-1.76
- -3.83%
- +1.2%
- €2.08B
- 0.83
- €25.71 – €53.92
- 0.23%
- Apr 27, 2026
- Nov 3, 2026 (62 days)
As of Sep 1, 2026
Upcoming catalysts
- Earnings report
As of Sep 1, 2026
Latest news
As of Sep 1, 2026
MonkeyTrade's Take on Bayer AG
Short-term outlook
Bayer's short-term setup leans mildly bullish but without much conviction: the stock sits above both its 50-day and 200-day averages, and the 1-month gain of +2.1% supports that tilt, though the MACD's bearish tick and neutral RSI at 55.8 keep momentum in check. A push through €49.45 resistance would firm up the bullish case, while a slip below €47.44 support would tip the balance the other way. No earnings until Nov 3, 2026, so no near-term catalyst is expected to disrupt this range.
Medium-term outlook
Bayer's numbers over the next few quarters don't give much to lean on: revenue growth is barely positive at +1.2%, the company is still posting a -3.8% profit margin, and the dividend yield sits at a thin +0.2%. With the technical picture also neutral, there's no clear directional edge here — a swing back to profitability would be the key development to change that.
Key risks
- Bayer is currently unprofitable, with a negative profit margin, which raises questions about near-term earnings quality despite modest revenue growth.
- The stock trades near the top of its 52-week range, having moved a long way from its €25.71 low, leaving less room for error if sentiment turns.
- Ongoing Roundup litigation remains unresolved, and continued court detours around the $7.25 billion settlement plan point to lingering legal and financial uncertainty.
- Reliance on pipeline developments such as the REVEAL study means clinical or regulatory setbacks could weigh on sentiment given the company's already thin margins.
About Bayer AG
Bayer AG is a German healthcare company listed on XETRA under the ticker BAYN, operating in the drug manufacturers - general industry. As one of the country's largest pharmaceutical names, Bayer holds a broad footprint that spans prescription medicines and life-science research, giving it a recognised position within the global healthcare sector.
The company's key figures give a snapshot of where it currently stands. A market capitalisation of €48.2B reflects its scale within the healthcare industry. There is no price-to-earnings ratio available, meaning that particular valuation gauge cannot be assessed from current data. Its dividend yield sits at +0.2%, a modest figure for income-focused readers to note. Together, these metrics offer a factual starting point for anyone researching Bayer's standing before digging further into its financial reports and market activity.
How to trade Bayer AG
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.